Skip to content
← All treatment topics

TREATMENT READING

Childhood Chordoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Childhood Chordoma

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

One report described the value of using a multidisciplinary clinic for patients with these very rare tumors.[1] Treatment options for childhood chordoma include the following:

Sources: 1

Surgery with or without radiation therapy.

Sources: Surgery with or without radiation therapy

Tyrosine kinase inhibitor (TKI) therapy.

Sources: Tyrosine kinase inhibitor (TKI) therapy

Health professional · Treatment of Childhood Chordoma

Surgery With or Without Radiation Therapy

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Standard treatment includes surgery and external radiation therapy, often proton-beam radiation.[2,3] Surgery is often not curative in children and adolescents because of the likelihood of the chordomas arising in the skull base, rather than in the sacrum, making them relatively inaccessible for complete surgical excision. However, if gross-total resection can be achieved, outcome is improved.[4][Level of evidence C1]

Sources: 2 · 3 · 4 · Level of evidence C1

The best results have been obtained using proton-beam therapy (charged-particle radiation therapy) because these tumors are relatively radiation resistant, and radiation-dose conformality with protons allows for higher tumor doses while sparing adjacent critical normal tissues.[5-8]; [2,9][Level of evidence C1]; [10][Level of evidence C2]

Sources: charged-particle radiation therapy · 5 · 8 · 2 · 9 · Level of evidence C1 · 10 · Level of evidence C2

Evidence (surgery and/or radiation therapy):

In a retrospective study of 20 children with skull-based chordomas, the median age at diagnosis was 12 years. The most common presenting symptoms were diplopia, headache, and swallowing difficulties.[11] Five patients had locally recurrent tumors. Twelve patients underwent surgery with an endoscopic endonasal approach alone, and eight patients underwent other procedures. All but two patients received radiation therapy. Fourteen patients had gross-total resections, ten of whom developed surgical complications.

Sources: 11

In a retrospective study of 20 children with skull-based chordomas, the median age at diagnosis was 12 years. The most common presenting symptoms were diplopia, headache, and swallowing difficulties.[11] Five patients had locally recurrent tumors. Twelve patients underwent surgery with an endoscopic endonasal approach alone, and eight patients underwent other procedures. All but two patients received radiation therapy. Fourteen patients had gross-total resections, ten of whom developed surgical complications.

No differences in recurrence rates were seen between patients who presented with a new diagnosis and patients who had recurrent disease or between patients who underwent a gross-total resection and patients who underwent a near-total resection.

Of patients who received postoperative radiation therapy, none had a recurrence.

Comparatively, of the 11 patients who either did not receive radiation therapy or were treated preoperatively, 4 had a recurrence (P = .09).

Three patients developed distant metastases, and three patients died of disease.

A high Ki-67 index was more prevalent among patients with dedifferentiated chordomas. Two of the three patients who died had an elevated Ki-67 index.

Pediatric patients with base-of-skull chordomas were treated with proton-beam therapy or a combined proton/photon approach (proton-based; most received 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Of 204 patients, the median age at diagnosis was 11.1 years (range, 1–21 years).[12]

Sources: 12

Pediatric patients with base-of-skull chordomas were treated with proton-beam therapy or a combined proton/photon approach (proton-based; most received 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Of 204 patients, the median age at diagnosis was 11.1 years (range, 1–21 years).[12]

The chordomas presented in the upper and/or middle clivus in 59% of the patients, lower clivus in 36%, craniocervical junction in 4%, and nasal cavity in 1%.

The median overall survival (OS) was 26 years, and the median progression-free survival (PFS) was 25 years. The 5-, 10-, and 20-year OS rates were 84%, 78% and 64%, respectively. The 5-, 10-, and 20-year PFS rates were 74%, 69%, and 64%, respectively.

In multivariable actuarial analysis, prognostic factors associated with worse OS included poorly differentiated subtype, radiographical progression prior to radiation therapy, larger treatment volume, and lower clivus location.

Health professional · Treatment of Childhood Chordoma

Tyrosine Kinase Inhibitor (TKI) Therapy

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Chordomas overexpress PDGFRA, PDGFRB, and KIT. Because of this finding, imatinib mesylate has been studied in adults with chordomas.[13,14]

Sources: 13 · 14

In one study, 50 adults with chordomas were treated with imatinib and evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. One patient had a partial response and 28 additional patients had stable disease at 6 months.[14] The low rate of RECIST responses and the potentially slow natural course of the disease complicate the assessment of the efficacy of imatinib for chordoma.[14]

Sources: 14 · 14

Other TKIs and combinations involving TKIs have been studied in adults.[15-17]

Sources: 15 · 17

One multicenter French retrospective study reported five patients who had partial responses to treatment with either imatinib, sorafenib, or erlotinib. The median PFS was 36 months.[18]

Sources: 18

Health professional · Treatment of Childhood Chordoma

Chemotherapy

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

There are only a few anecdotal reports of the use of cytotoxic chemotherapy after surgery alone or surgery plus radiation therapy. Treatment with ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide was beneficial in some reports.[19,20] The role for chemotherapy in the treatment of this disease is uncertain.

Sources: 19 · 20

Recurrences are usually local but can include distant metastases to the lungs or bone.

Health professional

Treatment Options Under Clinical Evaluation for Childhood Chordoma

Source: Childhood Chordoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

PEPN2121 (NCT05286801) (Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1- or SMARCA4-Deficient Tumors): This study is evaluating the combination of a PD-L1 targeting antibody (atezolizumab) with a TIGIT targeting antibody (tiragolumab) for patients with SMARCB1- or SMARCA4-deficient tumors.

Sources: PEPN2121 (NCT05286801)

For patients

Treatment of childhood chordoma

Source: Childhood Chordoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

There are different types of treatment for children and adolescents with chordoma. You and your child's care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the tumor is newly diagnosed or has come back.

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

For patients · Treatment of childhood chordoma

Surgery

Source: Childhood Chordoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgery may be used to remove as much of the tumor as possible. If the chordoma formed in or near the brain, or by important nerves or blood vessels, it cannot be completely removed by surgery without causing harm to your child.

Sources: nerves · blood vessels

For patients · Treatment of childhood chordoma

Radiation therapy

Source: Childhood Chordoma (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Childhood chordoma may be treated with external beam radiation therapy. External beam radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Proton beam radiation therapy is a type of high-energy, external radiation therapy that aims streams of protons (tiny, invisible, positively charged particles) at the cancer cells to kill them. This type of radiation therapy may be used for tumors near the base of the skull.

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.

Disease and treatment settings

Childhood Chordoma

Disease and treatment setting

Chordoma in children and adolescents